We are thrilled to announce that our research contribution to the development of the RENOVAC vaccine has been published in MDPI Vaccines! This marks a significant achievement for the Institute of Applied Biological Research and Development (IABRD) a division of Nirav Biosolutions Pvt. Ltd. Pune, as we play a key role in advancing the fight against coronavirus through scientific research.

The study, titled "Development, Pre-Clinical Safety, and Immune Profile of RENOVAC—A Dimer RBD-Based Anti-Coronavirus Subunit Vaccine," explores the intricate details of RENOVAC, an innovative subunit vaccine designed to target the coronavirus. Our research team focused on immunophenotyping using Flow Cytometry and studying cytokine storm responses through Luminex xMAP technology, tools that are essential in understanding immune reactions and vaccine safety at a deep level.

In addition to our efforts, we are deeply grateful for the collaboration with the Center for Advanced Technologies, Tashkent 100174, Uzbekistan, and the PRADO-Preclinical Research and Development Organization. Their partnership allowed us to contribute to this critical work, which has the potential to make a real difference in the global battle against COVID-19.

For those interested in learning more about the details of our study, the full article can be accessed here: Read The Full Article Here!

This publication highlights not only the hard work and dedication of our team but also the importance of collaborative global efforts in scientific research. We are proud to be part of such a groundbreaking project and look forward to continuing our contributions to the development of safe and effective vaccines.